OtoVia Therapeutics · Gene Therapy · Interventional/NA
UnknownTherapeutic
Population
Children & adults · ≥1 year; no upper limit listed
Biallelic OTOF DFNB9 severe-to-total deafness
Evidence
registry+publication
Confidence
86%
Indications
Hearing LossSensorineural Hearing LossGenetic Hearing LossDFNB9
